Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2009-06-05 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about clinical trial results for the drug Ilaris, including study design, efficacy, safety, and regulatory status. The document is an investor relations release providing new data and updates on the drug's development and regulatory review. It is not an annual or quarterly financial report, audit report, or earnings release. It is not a transcript, management or board change announcement, or a capital/financing update. The document is a regulatory filing providing material information to investors and the SEC about ongoing clinical development and regulatory progress. Given the nature of the content and the form type (6-K), the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory disclosure.
2009-06-05 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content focuses on an investor relations release announcing the successful launch of a EUR 1.5 billion notes issue under its Euro Medium Term Note Programme. It includes details about the notes, pricing, maturity, credit ratings, and use of proceeds. The document is primarily an announcement of a capital raising event (notes issuance) rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed management discussion. The length is 7,524 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2009-06-04 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing FDA approval of a drug (Reclast) for a new indication. It includes detailed product information, study results, and forward-looking statements. There are no financial statements, quarterly or annual financial data, or management discussion and analysis sections typical of financial reports. The document is not a full annual or interim report, nor is it a transcript, audit report, or governance-related document. It is a regulatory filing providing material information to investors and the SEC but does not fit into other specific categories such as earnings release or capital update. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific types.
2009-06-02 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of Afinitor for advanced kidney cancer in the European Union. It includes clinical trial data summaries, safety information, and forward-looking statements. There are no detailed financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management change announcement. It is a regulatory filing providing material information to investors and the SEC but does not constitute a full financial report or earnings release. Given the nature and format, this filing best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2009-06-02 English
4
Director's Dealing
2009-05-29 English
6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations release announcing an increase in the offer price for Novartis India Ltd., which is related to a proposed acquisition. The document includes disclaimers about forward-looking statements and details about the offer price revision. There are no financial statements or detailed financial analysis present, and the document is not a full annual or interim report. It is also not a transcript, audit report, or governance information. The document is an announcement related to a merger/acquisition activity, specifically an update on the offer price in a takeover bid. Therefore, the most appropriate classification is M&A Activity (TAR). The document length (7394 characters) supports it being a substantive announcement rather than a brief notice or certification.
2009-05-29 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.